Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

About this update from Phio Pharmaceuticals Corp.

[{"type":"text","content":"Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend","length":94,"tagName":"p"},{"type":"text","content":"Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein","length":121,"tagName":"p"},{"type":"text","content":"King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board Certified, licensed dermatologist who will explore both prevention and next-generation treatment strategies for various forms of skin cancer.","length":634,"tagName":"p"},{"type":"text","content":""We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Spellman will discuss the future direction of dermatologic oncology and highlight how our INTASYL® siRNA program represents a differentiated and innovative approach to immuno-oncology."","length":353,"tagName":"p"},{"type":"text","content":"DATE: Tuesday May 19, 2026","length":26,"tagName":"p"},{"type":"text","content":"TIME: 4 PM EDT","length":14,"tagName":"p"},{"type":"text","content":"REGISTRATION LINK: PHIO Pharma - Force Family Office","length":52,"tagName":"p"},{"type":"text","content":"Recent Company Highlights","length":25,"tagName":"p"},{"type":"text","content":"Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.","length":545,"tagName":"p"},{"type":"text","content":"Phio ha...

More updates from Phio Pharmaceuticals Corp.